MADD028

Remedy Acceptance vs Deal Economics

Business ContextRegulators may require divestitures, behavioral commitments, access obligations, or other remedies before approving a transaction. Accepting remedies can preserve completion, but excessive concessions may remove assets, capabilities, or synergies central to the acquisition thesis.

Mergers and Acquisitions TRIZ ResolutionEvaluate remedies against specific sources of transaction value. Design targeted alternatives that address regulatory concerns while preserving the capabilities and economics essential to the investment case.

Applicable TRIZ Principles

Principle 2 – Taking Out removes only elements responsible for the regulatory concern.

Principle 3 – Local Quality applies remedies specifically where concerns arise.

Principle 15 – Dynamics adapts transaction structure while preserving core value.

Expected Outcome

Higher approval probability

Better preservation of deal economics

More targeted remedies

Stronger walk-away discipline

Decision IndicatorsEarly indicators that this contradiction is limiting M&A performance include:

Proposed remedies eliminate major expected synergies.

Approval becomes more important than preserving investment returns.

Remedy economics are excluded from valuation.

Broad concessions are accepted without testing narrower alternatives.

The transaction thesis changes materially during regulatory review.

Monitoring these indicators helps obtain approval without preserving a transaction whose economics have been materially weakened.